Merissa – 杏國新藥股份有限公司

SynCore Biotechnology Announces Interim Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1)

SynCore Biotechnology (4192:TT) receives interim analysis results for its [...]

Merissa2020-08-14T16:56:21+08:00August 11th, 2020|Press Release|

SynCore Biotechnology (SynCore Bio) is pleased to announce that [...]

Merissa2020-07-21T14:56:02+08:00July 21st, 2020|Latest Events|

SynCore Biotechnology (SynCore Bio) is pleased to announce that [...]

Merissa2020-05-20T14:42:38+08:00May 20th, 2020|Latest Events|

SynCore’s global phase III clinical trial on pancreatic cancer [...]

Merissa2020-05-25T17:20:18+08:00May 7th, 2020|Press Release|

Topic: 2019 Symposium on Research Development in Dry Age-Related [...]

Merissa2019-07-30T09:08:42+08:00July 30th, 2019|Latest Events|

China NMPA Approves SynCore Biotechnology to Conduct Phase III [...]

Merissa2019-08-12T19:05:11+08:00June 16th, 2019|Press Release|

Event Datetime 2019.07.27 (Sat) 1:30-5:20 pm (GMT+8) Event [...]

Merissa2019-07-19T00:50:24+08:00June 14th, 2019|Latest Events|

Event Datetime 2019.03.16 (Sat) 13:00-14:40 (GMT+8) Event Location [...]

Merissa2019-03-13T11:57:23+08:00March 13th, 2019|Latest Events|

Taipei, Taiwan, 14 January 2019. SynCore Biotechnology Co. (4192:TT) announces [...]

Merissa2019-01-22T23:33:38+08:00January 14th, 2019|Press Release|

Taipei, Taiwan, 25 December 2018. SynCore Biotechnology Co. (4192:TT) [...]

Merissa2019-01-03T18:52:50+08:00December 25th, 2018|Press Release|